Filing Flows › BeOne Medicines (ONC) › Q1 2025
BeOne Medicines (ONC) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
BeOne Medicines (ONC) reported revenue of $1.1B for the first quarter 2025 (Q1 2025), +49% from a year earlier and -0.9% from the quarter before. Operating margin was 1.0%, net earnings $1.3M (0.1% of revenue).
BeOne Medicines, Q1 2025: revenue $1.1B (+49% year over year), operating margin 1.0%, net earnings $1.3M, operating cash flow $44.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1B | -0.9% | +49% |
| Gross profit | $952M | -2% | +52% |
| Operating profit | $11.1M | — | — |
| Net earnings | $1.3M | — | — |
| Operating cash flow | $44.1M | -41% | — |
What changed
Revenue was $1.1B in Q1 2025, up 49% year over year and down 1% from the previous quarter. Product revenue, net was the largest line at 99% of revenue. Product revenue, net added $0.36B year over year (up 48%), 99% of the total change.
Gross margin was 85.2%, up 1.9 points from a year earlier. Operating profit was $0.01B, a 1.0% margin (up 35.8 points year over year). Operating expenses grew 6% against revenue growth of 49%. Net earnings were $1.3M. The effective tax rate was 93.9%. Non-operating items added $0.01B, 47% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $0.04B, 3471% of net earnings. Non-cash charges added back $0.03B of depreciation and amortization and $0.10B of share-based compensation. Working capital and other items used $0.09B. Capital expenditures of $0.06B exceeded it, leaving free cash flow of −$0.01B.
Questions
What was BeOne Medicines' revenue in the first quarter 2025?
BeOne Medicines (ONC) reported revenue of $1.1B for the first quarter 2025 (Q1 2025), +49% from a year earlier and -0.9% from the quarter before.
Was BeOne Medicines profitable in the first quarter 2025?
Operating profit was $11.1M (1.0% of revenue) and net earnings $1.3M.
Source: BeOne Medicines 10-Q on SEC EDGAR.